RedShift BioAnalytics Receives $20 Million Series E Financing Led by Illumina Ventures
Bowen Serves as 3x Financial Advisor to RedShiftBio
BOSTON, October 27, 2021 – Bowen is pleased to announce that RedShift BioAnalytics (RedShiftBio) has received $20 million in Series E funding led by financial investor Illumina Ventures. The company’s shareholders, including Technology Venture Partners, strategic investor Waters (NYSE: WAT) and a second strategic investor also participated in the round. Bowen acted as the exclusive financial advisor to RedShiftBio for the third time, having also advised RedShiftBio on its 2017 Series C and 2019 Series D financings.
RedShiftBio is an innovative Life Sciences instrumentation and software company that measures previously undetectable changes in protein structure, critical to drug efficacy and quality. The company has demonstrated its ability to provide ultra-precise and accurate structural elucidation for high growth biomolecular areas within biopharma such as protein-based biologics, AAVs, ligand binding and mRNA-based therapeutics.
“Since Bowen first became involved with RedShiftBio, the company has made tremendous progress bringing to market our revolutionary technology that helps the biopharmaceutical industry develop better drugs faster,” said Julien Bradley, RedShiftBio CEO. “Bowen provided the company with invaluable expertise in efficiently securing the capital necessary to accelerate our growth through their deep relationships and understanding of the industry.”
- Bowen’s Healthcare Tech practice
- Bob Fleming, Managing Director and Head of Healthcare Tech
- RedShiftBio’s press release